DarioHealth (DRIO) to Release Earnings on Wednesday

Key Points

• Earnings release: DarioHealth will report Q1 2026 results before the market opens on Wednesday, May 13, 2026, with analysts forecasting a loss of ($1.48) per share and revenue of $5.456 million; the earnings call is scheduled for 8:30 AM ET.
• Stock and valuation: Shares jumped about 7.2% and opened at $7.99, trading within a 1‑year range of $5.93–$17.74, with a market cap of $58.3 million and a negative PE of -0.77.
• Investor and analyst activity: Institutional investors own roughly 33.4% of the stock with recent stake increases from XTX Topco and Geode, while analyst coverage is mixed (two Buys, one Hold, one Sell) and the consensus rating is "Hold" with an average target of $35.00.

DarioHealth (NASDAQ:DRIO - Get Free Report) is projected to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect DarioHealth to post earnings of ($1.48) per share and revenue of $5.4560 million for the quarter. Interested persons can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

DarioHealth Stock Up 7.2%

DarioHealth stock opened at $7.99 on Wednesday. DarioHealth has a 1-year low of $5.93 and a 1-year high of $17.74. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.76 and a quick ratio of 3.30. The stock has a market cap of $58.33 million, a PE ratio of -0.77 and a beta of 1.09. The stock's fifty day moving average is $8.46 and its two-hundred day moving average is $10.84.

Hedge Funds Weigh In On DarioHealth

A number of hedge funds and other institutional investors have recently made changes to their positions in DRIO. XTX Topco Ltd grew its holdings in shares of DarioHealth by 229.0% during the second quarter. XTX Topco Ltd now owns 62,511 shares of the company's stock worth $42,000 after buying an additional 43,513 shares during the last quarter. Geode Capital Management LLC boosted its holdings in DarioHealth by 167.9% in the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company's stock valued at $564,000 after purchasing an additional 31,063 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in DarioHealth in the 4th quarter valued at approximately $35,000. Hedge funds and other institutional investors own 33.39% of the company's stock.

Analyst Ratings Changes

Several equities analysts have issued reports on DRIO shares. Wall Street Zen lowered DarioHealth from a "hold" rating to a "sell" rating in a report on Sunday, January 25th. Stifel Nicolaus dropped their price objective on DarioHealth from $16.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, March 20th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $35.00.

DarioHealth Company Profile

DarioHealth NASDAQ: DRIO is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.